Phoenix Molecular Designs
Phoenix Molecular Designs is a biotech company in Vancouver, Canada, founded in 2012. It has raised $14.7M across 2 rounds, most recently a $12.0M Seed in November 2019.
- Headquarters
- Vancouver
- Founded
- 2012
- Website
- phoenixmd.ca
- Total Funding
- $14.7M
- Last Round
- $12.0M SeedNov 2019
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 1 investor for this company. The full record is or through the API.
About
Phoenix Molecular Designs was founded by Dr. Sandra Dunn in 2012 with a singular vision to transform the way breast cancer is treated. Her work has contributed to the discovery and development of PMD-026, a first-in-class RSK2 inhibitor currently in Phase 2 clinical trials, advancing therapies aimed at improving outcomes for women facing breast cancer.
Summary
It has raised $14.7M in total across 2 rounds, most recently a $12.0M Seed round in Nov 2019. Investors include Pallasite Ventures.
Funding History
Nov 2019
Sign up to see all 2 events
Funding: Venture Round through Seed. Amounts, valuations, and investors where available.
Investors
Similar Companies
Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/phoenix-molecular-designs"><img src="https://indexed.vc/api/badge/company/phoenix-molecular-designs" alt="Phoenix Molecular Designs on Indexed.vc" width="260" height="76" /></a>